Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 1/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 5/20 | 0.37 |
| ▸ | MAOA | P21397 | 4/20 | 0.37 |
| ▸ | MAOB | P27338 | 4/20 | 0.37 |
| ▸ | TACR1 | P25103 | 1/20 | 0.35 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
| ▸ | GBA1 | P04062 | 1/20 | 0.34 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29081784 | 0.82 | PRCP (0.36) | PRCPTRPA1KDM1AMAOAMAOB | |
| SCHEMBL31145132 | 0.82 | PRCP (0.36) | PRCPTRPA1KDM1AMAOAMAOB | |
| SCHEMBL29081786 | 0.82 | PRCP (0.36) | PRCPTRPA1KDM1AMAOAMAOB | |
| SCHEMBL24365235 | 0.82 | PRCP (0.36) | PRCPTRPA1KDM1AMAOAMAOB | |
| SCHEMBL3574526 | 0.81 | KDM1A (0.44) | PRCPKDM1AMAOAMAOBGBA1 | |
| SCHEMBL9420060 | 0.77 | PRCP (0.40) | PRCPTRPA1KDM1AMAOAMAOB | |
| SCHEMBL549369 | 0.75 | CHRNB2 (0.33) | SIGMAR1CHRNB2CHRNA4 | |
| SCHEMBL549368 | 0.75 | CHRNB2 (0.33) | SIGMAR1CHRNB2CHRNA4 | |
| SCHEMBL1274272 | 0.75 | CHRNB2 (0.36) | KDM1AMAOBCHRNB2CHRNA4 | |
| SCHEMBL13825670 | 0.72 | BRD4 (0.36) | CHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| CN-116568677-A | piperidin-1-yl-N-pyridin-3-yl-2-oxoacetamide derivatives useful for the treatment of MTAP deficiency and/or MTA accumulating cancers | 探戈医药股份有限公司 | 2023-08-08 | — | — | CN | disclosed |
| US-20220127256-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2022-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220127256-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | PRCP 444/4885TRPA1 848/4885KDM1A 2941/4885 |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | PRCP 444/4885TRPA1 848/4885KDM1A 2941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.